{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:18:58Z","timestamp":1769167138890,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Medical Scientific research project of Chongqing Municipal Health Commission","award":["2023WSJK014"],"award-info":[{"award-number":["2023WSJK014"]}]},{"name":"Excellent Youth Program of the Basic Medical college of Chongqing Medical University","award":["Excellent Youth Program of the Basic Medical college of Chongqing Medical University"],"award-info":[{"award-number":["Excellent Youth Program of the Basic Medical college of Chongqing Medical University"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-05084-0","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T08:01:52Z","timestamp":1717747312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of transcutaneous electrical nerve stimulation combined with mirabegron therapy compared with mirabegron monotherapy for overactive bladder: a prospective randomized controlled study"],"prefix":"10.1007","volume":"42","author":[{"given":"Liang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanghao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JinJin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"5084_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","volume":"202","author":"DJ Lightner","year":"2019","unstructured":"Lightner DJ, Gomelsky A, Souter L, Vasavada SP (2019) Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA\/SUFU Guideline Amendment 2019. J Urol 202:558\u2013563","journal-title":"J Urol"},{"key":"5084_CR2","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/j.1464-410X.2011.10498.x","volume":"108","author":"TL Griebling","year":"2011","unstructured":"Griebling TL (2011) Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence, and bladder outlet obstruction. BJU Int 108:1138\u20131139","journal-title":"BJU Int"},{"key":"5084_CR3","doi-asserted-by":"crossref","unstructured":"Raju R, Linder BJ (2020) Evaluation and Treatment of Overactive Bladder in Women. Mayo Clin Proc. ;95:370\u20137","DOI":"10.1016\/j.mayocp.2019.11.024"},{"key":"5084_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2022.01.045","volume":"82","author":"AK Nambiar","year":"2022","unstructured":"Nambiar AK, Arlandis S, B\u00f8 K, Cobussen-Boekhorst H, Costantini E, de Heide M et al (2022) European Association of Urology Guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: Diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol 82:49\u201359","journal-title":"Eur Urol"},{"key":"5084_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1517\/17425247.2016.1130033","volume":"13","author":"K Scott","year":"2016","unstructured":"Scott K, Dmochowski RR, Padmanabhan P (2016) Delivery methods for drugs used in the treatment of overactive bladder. Expert Opin Drug Deliv 13:361\u2013371","journal-title":"Expert Opin Drug Deliv"},{"key":"5084_CR6","first-page":"CD013571","volume":"10","author":"S Funada","year":"2023","unstructured":"Funada S, Yoshioka T, Luo Y, Sato A, Akamatsu S, Watanabe N (2023) Bladder training for treating overactive bladder in adults. Cochrane Database Syst Rev 10:CD013571","journal-title":"Cochrane Database Syst Rev"},{"key":"5084_CR7","first-page":"CD003781","volume":"5","author":"A Stoniute","year":"2023","unstructured":"Stoniute A, Madhuvrata P, Still M, Barron-Millar E, Nabi G, Omar MI (2023) Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst Rev 5:CD003781","journal-title":"Cochrane Database Syst Rev"},{"key":"5084_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","volume":"74","author":"C Gratzke","year":"2018","unstructured":"Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D et al (2018) Long-term safety and efficacy of Mirabegron and Solifenacin in Combination compared with Monotherapy in patients with overactive bladder: a Randomised, Multicentre phase 3 study (SYNERGY II). Eur Urol 74:501\u2013509","journal-title":"Eur Urol"},{"key":"5084_CR9","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00345-016-1908-1","volume":"35","author":"P Abrams","year":"2017","unstructured":"Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I et al (2017) Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY). World J Urol 35:827\u2013838","journal-title":"World J Urol"},{"key":"5084_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.eururo.2016.08.061","volume":"71","author":"D Newgreen","year":"2017","unstructured":"Newgreen D, Bosman B, Hollestein-Havelaar A, Dahler E, Besuyen R, Sawyer W et al (2017) Solifenacin in children and adolescents with overactive bladder: results of a phase 3 Randomised Clinical Trial. Eur Urol 71:483\u2013490","journal-title":"Eur Urol"},{"key":"5084_CR11","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41585-018-0049-2","volume":"15","author":"CA Bradley","year":"2018","unstructured":"Bradley CA (2018) Mirabegron and solifenacin for OAB. Nat Rev Urol 15:526","journal-title":"Nat Rev Urol"},{"key":"5084_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","volume":"77","author":"CR Chapple","year":"2020","unstructured":"Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N et al (2020) Safety and Efficacy of Mirabegron: analysis of a large Integrated Clinical Trial Database of patients with overactive bladder receiving Mirabegron, Antimuscarinics, or Placebo. Eur Urol 77:119\u2013128","journal-title":"Eur Urol"},{"key":"5084_CR13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.euf.2018.05.004","volume":"4","author":"T Marcelissen","year":"2018","unstructured":"Marcelissen T, Cornu JN, Antunes-Lopes T, Geavlete B, Delongchamps NB, Rashid T et al (2018) Management of idiopathic overactive bladder syndrome: what is the optimal strategy after failure of Conservative Treatment. Eur Urol Focus 4:760\u2013767","journal-title":"Eur Urol Focus"},{"key":"5084_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/luts.12188","volume":"11","author":"D Kato","year":"2019","unstructured":"Kato D, Tabuchi H, Uno S (2019) Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study. Low Urin Tract Symptoms 11:14\u201323","journal-title":"Low Urin Tract Symptoms"},{"key":"5084_CR15","first-page":"429","volume":"28","author":"C Sze","year":"2022","unstructured":"Sze C, Drangsholt S, Stoddard MD, Singh Z, Sansone S, Bhojani N et al (2022) Adverse events for overactive bladder medications from a Public Federal Database. Female Pelvic Med Reconstr Surg 28:429\u2013435","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"5084_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/PHM.0000000000001836","volume":"101","author":"Y Liu","year":"2022","unstructured":"Liu Y, Xu G, Geng J (2022) Efficacy of Transcutaneous Electrical Nerve Stimulation in the management of neurogenic overactive bladder: a Randomized Controlled Trial. Am J Phys Med Rehabil 101:2\u201310","journal-title":"Am J Phys Med Rehabil"},{"key":"5084_CR17","doi-asserted-by":"publisher","first-page":"e0253040","DOI":"10.1371\/journal.pone.0253040","volume":"16","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Wang S, Zu S, Zhang C (2021) Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: a double-blind randomized controlled study. PLoS ONE 16:e0253040","journal-title":"PLoS ONE"},{"key":"5084_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/nau.23863","volume":"38","author":"J Wang","year":"2019","unstructured":"Wang J, Zhou Z, Cui Y, Li Y, Yuan H, Gao Z et al (2019) Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn 38:22\u201330","journal-title":"Neurourol Urodyn"},{"key":"5084_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/luts.12262","volume":"11","author":"LC Chen","year":"2019","unstructured":"Chen LC, Kuo HC (2019) Pathophysiology of refractory overactive bladder. Low Urin Tract Symptoms 11:177\u2013181","journal-title":"Low Urin Tract Symptoms"},{"key":"5084_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1590\/s1677-5538.ibju.2015.0719","volume":"43","author":"CV Scaldazza","year":"2017","unstructured":"Scaldazza CV, Morosetti C, Giampieretti R, Lorenzetti R, Baroni M (2017) Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. Int Braz J Urol 43:121\u2013126","journal-title":"Int Braz J Urol"},{"key":"5084_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2217\/pmt-2016-0030","volume":"7","author":"MI Johnson","year":"2017","unstructured":"Johnson MI, Jones G (2017) Transcutaneous electrical nerve stimulation: current status of evidence. Pain Manag 7:1\u20134","journal-title":"Pain Manag"},{"key":"5084_CR22","doi-asserted-by":"publisher","first-page":"101486","DOI":"10.1016\/j.rehab.2021.101486","volume":"65","author":"R Sonmez","year":"2022","unstructured":"Sonmez R, Yildiz N, Alkan H (2022) Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: a prospective randomised controlled trial. Ann Phys Rehabil Med 65:101486","journal-title":"Ann Phys Rehabil Med"},{"key":"5084_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/nau.24812","volume":"41","author":"N Pedersen","year":"2022","unstructured":"Pedersen N, Breinbjerg A, Thorsteinsson K, Hagstr\u00f8m S, Rittig S, Kamperis K (2022) Transcutaneous electrical nerve stimulation as add-on therapy in children receiving anticholinergics and\/or mirabegron for refractory daytime urinary incontinence: a retrospective cohort study. Neurourol Urodyn 41:275\u2013280","journal-title":"Neurourol Urodyn"},{"key":"5084_CR24","doi-asserted-by":"crossref","unstructured":"Le\u00e3o S, Santos H, Caldwell P, Hussong J, von Gontard A, Estevam de Abreu G, Braga AA et al (2022) Quality of life and psychological aspects in children with overactive bladder treated with parasacral transcutaneous electrical nerve stimulation - A prospective multicenter study. J Pediatr Urol. ;18:739.e1-739.e6","DOI":"10.1016\/j.jpurol.2022.10.011"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05084-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05084-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05084-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:32:55Z","timestamp":1735853575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05084-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5084"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05084-0","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"17 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"370"}}